Draft Guidance for Industry; Availability:
Federal Register Volume 76, Number 168 (Tuesday, August 30, 2011)
Notices
Pages 53909-53910
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
FR Doc No: 2011-22146
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket No. FDA-2011-D-0595
Draft Guidance for Industry on Tablet Scoring: Nomenclature,
Labeling, and Data for Evaluation; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ``Tablet
Scoring: Nomenclature, Labeling, and Data for Evaluation.'' This draft guidance provides recommendations to sponsors of new drug applications
(NDAs) and abbreviated new drug applications (ANDAs) regarding what criteria should be met to facilitate the evaluation and labeling of tablets that have been scored. (A scoring feature facilitates tablet splitting, which is the practice of breaking or cutting a higher- strength tablet into smaller portions.) Specifically, this draft guidance recommends guidelines to follow, data to provide, and criteria to meet and detail in an application to approve a scored tablet; and nomenclature and labeling for approved scored tablets.
This guidance does not address specific finished-product release testing, where additional requirements may be appropriate for scored tablets.
DATES: Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by November 28, 2011.
ADDRESSES: Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document.
Submit electronic comments on the draft guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Russell Wesdyk, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 4182, Silver Spring, MD 20993-0002, 301- 796-2400.
SUPPLEMENTARY INFORMATION:
-
Background
FDA is announcing the availability of a draft guidance for industry entitled ``Tablet Scoring: Nomenclature, Labeling, and Data for
Evaluation.'' This draft guidance provides recommendations to sponsors of NDAs and ANDAs regarding what criteria should be met to facilitate the evaluation and labeling of tablets that have been scored. (A scoring feature facilitates tablet splitting, which is the practice of breaking or cutting a higher-strength tablet into smaller portions.)
Specifically, this draft guidance recommends:
Guidelines to follow, data to provide, and criteria to meet and detail in an application to approve a scored tablet.
Nomenclature and labeling for approved scored tablets.
The Agency has previously considered tablet scoring as an issue when determining whether a generic drug product is the same as the reference listed drug (RLD). One characteristic of a tablet dosage form is that it may be manufactured with a score or scores. This characteristic is useful because the score can be used to facilitate the splitting of the tablet into fractions when less than a full tablet is desired for a dose. Although there are no standards or regulatory requirements that specifically address scoring of tablets, the Agency recognizes the need for consistent scoring between a generic product and its RLD.
Consistent scoring ensures that the patient is able to adjust the dose, by splitting the tablet, in the same manner as the RLD. This enables the patient to switch between products made by different manufacturers without encountering problems related to the dose. In addition, consistent scoring ensures that neither the generic product nor the RLD has an advantage in the marketplace because one is scored and one is not.
CDER's Drug Safety Oversight Board considered the practice of tablet splitting at its October 2009 and November 2010 meetings. During those meetings, they discussed how insurance companies and doctors are increasingly recommending that patients split tablets, either to adjust the patients' dose or as a cost-saving measure.
Page 53910
Because of this, the Agency conducted internal research on tablet splitting and concluded that in some cases, there are possible safety issues, especially when tablets are not scored or evaluated for splitting. The Agency's concerns with splitting a tablet included variations in the tablet content, weight, disintegration, or dissolution, which can affect how much drug is present in a split tablet and available for absorption. In addition, there may be stability issues with splitting tablets.
Tablet splitting also is addressed in pharmacopeial standards. The
European Pharmacopeia currently applies accuracy of subdivision standards for scored tablets--and has at various times also included standards for content uniformity, weight variation, and loss of mass-- while the United States Pharmacopeia published a Stimuli article in 2009 proposing criteria for loss of mass and accuracy of subdivision for split tablets.\1\
\1\ Geoff Green et al., November-December 2009, 35(6),
``Pharmacopeial Standards for the Subdivision Characteristics of
Scored Tablets,'' Pharmacopeial Forum.
As an outgrowth of these discussions and developments, FDA is providing recommendations for application content regarding the scientific basis for functional scores on solid oral dosage form products to ensure the quality of both NDA and ANDA scored tablet products. To accomplish this, the Agency has developed consistent and meaningful criteria by which scored tablets can be evaluated and labeled. The criteria are as follows: (1) Provide a harmonized approach to chemistry, manufacturing, and controls reviews of scored tablets;
(2) ensure consistency in nomenclature (e.g., score versus bisect) and labeling; and (3) provide information through product labeling or other means to healthcare providers.
This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the Agency's current thinking on tablet scoring: nomenclature, labeling, and data for evaluation. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.
-
Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
-
The Paperwork Reduction Act of 1995
This draft guidance refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The collections of information in 21 CFR 201.57, 314.50, and 314.70 have been approved under OMB control numbers 0910-0572 (for section 201.57) and 0910-0001 (for part 314).
-
Electronic Access
Persons with access to the Internet may obtain the document at either http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http://www.regulations.gov.
Dated: August 25, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
FR Doc. 2011-22146 Filed 8-29-11; 8:45 am
BILLING CODE 4160-01-P
